Detailed Reading of Fund Q2 Reports: How Did Active Fund Managers Allocate Healthcare in Q2 and Market Outlook? 【China Merchants Healthcare】

English summary

1. Drug funds: Focus on innovative drugs and CXO, adjusting around positions and internal structure. Among 163 drug fund Q2 reports, 150 mentioned innovative drugs, 109 mentioned CXO and R&D outsourcing, 61 mentioned BD or out-licensing, 45 mentioned medical devices, and 21 mentioned traditional Chinese medicine. Specific operations mainly include: continuing to hold or increase positions in innovative drug companies with global competitiveness, clinical data catalysts, BD potential, and commercialization capability; allocating to CXO, CDMO, and life science upstream companies with improving orders and performance; some funds reduced positions in targets with disappointing clinical data, performance pressure, or fully priced early expectations, and adjusted towards innovative devices, export devices, API, etc. Market focus points include innovative drug BD progress, key clinical data, milestone revenue and overseas commercialization, as well as order changes for CXO in new molecular modalities such as GLP-1, peptides, ADC, and small nucleic acids. For traditional Chinese medicine, medical services, consumer healthcare, and hospital-related sectors, fund managers focus more on domestic demand recovery, policy changes, operational improvements, and valuation levels. ...